Sponsored content from SmallCaps Daily As Geopolitical Tensions Flare, SMX Becomes the Frontline Defender of Critical Rare Earth Supply Chains! In an era where global security is tested by rising conflict, particularly the escalating tensions between the U.S. and Iran, the need for reliable, traceable, and verifiable rare earth minerals has never been greater. Australia’s rare earth reserves play a pivotal role in supplying critical minerals essential for defense, advanced technology, and clean energy in the United States. Yet the complex, multi-stage supply chains of these materials remain vulnerable to disruption, mislabeling, and counterfeiting—risks that are amplified when national security is on the line. SMX (Security Matters) Public Limited (NASDAQ: SMX) has developed a molecular identity platform that embeds a permanent, verifiable signature directly into each material. This breakthrough ensures that rare earth minerals can be authenticated from extraction to manufacturing, providing governments, manufacturers, and defense contractors with an unprecedented level of transparency and protection. With its operational base in Singapore and a growing presence across Southeast Asia, SMX leverages a politically stable environment to serve as a reliable partner in global supply-chain integrity. The platform transforms conventional, paper-based verification systems into intelligent, self-reporting networks, capable of safeguarding critical materials even during conflict or geopolitical disruption. As the U.S.-Iran tensions threaten supply-chain certainty, SMX ensures that Australian rare earths continue to flow securely, reducing exposure to counterfeit components, sabotage, and industrial espionage. By embedding verification directly into materials, SMX strengthens both economic resilience and national security, delivering a future-proof solution for defense, energy, and technology sectors. Discover why SMX is securing the rare earth supply chain in an uncertain world while building shareholder value
This Month's Featured News CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsAuthored by Chris Markoch. Article Posted: 2/19/2026. 
Key Points - CRISPR Therapeutics’ Q4 reaction reflects longer-term optimism despite weak reported revenue tied to launch economics.
- CASGEVY adoption is a key narrative driver, but profitability hinges on timing, revenue-sharing mechanics, and pipeline progress.
- With substantial cash on hand, the near-term question is technical/entry risk, while the long-term question is execution.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today (From Brownstone Research)
 CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene-editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that rally may seem contradictory. The company posted a larger net loss than forecast, and revenue came in far below expectations. Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now. Click here and start to collect in the next 30 days. But CRISPR is a long-term story still in the early innings. The company has moved past proof-of-concept, yet investors will need patience: the major payoff as CRISPR moves into a mature growth phase is likely a year or two away. Putting the Earnings Report Into Context In December 2023, CRISPR received U.S. Food & Drug Administration (FDA) approval for CASGEVY, its flagship gene therapy for sickle cell disease and beta thalassemia. That was the first FDA approval of a therapy using CRISPR/Cas9 gene-editing technology. Still, CRSP stock is down roughly 19% since that announcement. Part of that reflects growth that was already priced in, but the company's revenue model with partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) also plays a role. The collaboration helped secure regulatory approval, but revenue recognition is tied to a cost-recovery arrangement: CRISPR only recognizes revenue after Vertex recoups certain launch and manufacturing expenses. As a result, while CASGEVY generated $54 million in the most recent quarter, CRISPR reported just $0.86 million of quarterly revenue. That contrast frames the investment thesis. On one hand, more patients are receiving CASGEVY; on the other, operating losses are growing as the company advances additional pipeline candidates. A key metric is the company's cash and investment balance of about $1.9 billion, which should provide a runway of roughly three to four years. The Pipeline Holds the Key Even if CASGEVY adoption accelerates, the one-time, high-cost nature of these treatments and payment models that stretch revenue recognition will make near-term financial results challenging. As with most biotechnology stocks, CRISPR's long-term value depends on its pipeline. One of the more promising candidates is CTX611, being developed to prevent dangerous blood clots (such as those caused by strokes or deep vein thrombosis). The therapy targets the Factor XI protein, aiming to reduce pathological clotting without impairing normal clotting needed for routine injuries. CRISPR is testing CTX611 (SRSD107) in a Phase 2 trial for total knee arthroplasty (TKA), where postoperative blood clots are a common complication. Early human data show CTX611 has been well tolerated and produced durable effects, with potential for dosing as infrequently as every six weeks using the company's siRNA platform, which also allows for designed reversibility. If larger trials confirm a lower bleeding risk plus convenient, infrequent dosing, CTX611 could address a roughly $20 billion global anticoagulation market and become a meaningful growth driver. One Thing to Check Before Getting Involved With CRSP Stock Analyst sentiment supports the "wait-and-see" narrative. The consensus rating is a Hold, with a couple of sell ratings included. That mix includes a recent Underweight rating from Morgan Stanley, which set a $33 price target — a level that would place the stock near its 52-week low. Technically, the chart could be a concern: as of this writing, CRSP was trading around its 200-day moving average, which has acted as support since November. A confirmed break below that level could attract more sellers and pressure the share price further. 
CRSP Stock Is One to Own, Not Trade It's been a bumpy ride for long-term CRSP shareholders, but the company has delivered substantial returns: since its 2016 IPO, total investor return exceeds 277%. That figure was helped in part by the speculative highs in 2020–2021, which also prompted some profit-taking afterward. The takeaway is that CRISPR Therapeutics is executing on its pipeline, but progress isn't as rapid as some investors hoped. CRSP may not suit short-term traders seeking quick, large swings, but it could appeal to investors with a multi-year horizon who can tolerate volatility for the potential of significant gains by the end of the decade.
| 
No comments:
Post a Comment